ArticleJournal of clinical pathology2001
Fas ligand upregulation is an early event in colonic carcinogenesis.
Article in Journal of clinical pathology, 2001. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 19 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
19 citing papers in PubMed, 55 citations in OpenAlex.
- Role of metalloproteases in the CD95 signaling pathways.Frontiers in immunology · 2022Review
- Retinoic acid morpholine amide (RAMA) inhibits expression of Fas ligand through EP1 receptor in colon cancer cells.Tumour biology : the journal of the International Society for Oncodevelopmental Biology and Medicine · 2016Article
- Inactivation of the transcription factor GLI1 accelerates pancreatic cancer progression.The Journal of biological chemistry · 2014Article
- Tissue expression of the proteins fas and fas ligand in colorectal cancer and liver metastases.Journal of gastrointestinal cancer · 2012Article
- Human FasL gene is a target of β-catenin/T-cell factor pathway and complex FasL haplotypes alter promoter functions.PloS one · 2011Article
- A common hereditary single-nucleotide polymorphism in the gene of FAS and colorectal cancer survival.Journal of cellular and molecular medicine · 2009Article
- Human and mouse colon cancer utilizes CD95 signaling for local growth and metastatic spread to liver.Gastroenterology · 2009Article
- Fas ligand expression in lynch syndrome-associated colorectal tumours.Pathology oncology research : POR · 2009Article
- Prostaglandin E2 stimulates Fas ligand expression via the EP1 receptor in colon cancer cells.British journal of cancer · 2008Article
- Requirement of inositol 1,4,5-trisphosphate receptors for tumor-mediated lymphocyte apoptosis.The Journal of biological chemistry · 2008Article
- Newly established tumourigenic primary human colon cancer cell lines are sensitive to TRAIL-induced apoptosis in vitro and in vivo.British journal of cancer · 2007Article
- Increase in autoantibodies against Fas (CD95) during carcinogenesis in the human colon: a hope for the immunoprevention of cancer?Cancer immunology, immunotherapy : CII · 2005Article
- Role of cytokines in promoting immune escape of FasL-expressing human colon cancer cells.World journal of gastroenterology · 2005Article
- Article
- Article
- Fas ligand mediates immune privilege and not inflammation in human colon cancer, irrespective of TGF-beta expression.British journal of cancer · 2003Article
- Expression of Fas ligand and caspase-3 contributes to formation of immune escape in gastric cancer.World journal of gastroenterology · 2003Article
- CD95 (Fas/APO-1)/CD95L in the gastrointestinal tract: fictions and facts.Virchows Archiv : an international journal of pathology · 2003Review
- The Fas-FasL system and colorectal tumours.Journal of clinical pathology · 2002Article
Corrections and comments
- Commented on by
Authors and funding
7 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
BACKGROUND/
aimsFas ligand (FasL) is a mediator of apoptosis via the Fas receptor (Fas/CD95/APO-1). Normal colonic epithelium expresses Fas, and appears to be relatively sensitive to Fas mediated apoptosis. Colonic adenocarcinomas coexpress FasL and Fas without undergoing widespread apoptosis. This study investigates the expression of FasL in colonic carcinogenesis from the earliest stages of the adenoma-carcinoma sequence.
methodsFasL expression was determined in colonic adenomas (n = 38) of varying degrees of dysplasia and histological type by immunohistochemistry. Adenomas that contained areas of carcinomatous change were included (n = 12 of 38). Normal colonic epithelium (n = 10), hyperplastic polyps (n = 8), and serrated adenomas (n = 3) from patients without colonic adenocarcinomas were used for comparison. Cell death was detected in situ in adenomas using TUNEL (terminal transferase mediated dUTP nick end labelling).
resultsIn normal colonic epithelium and hyperplastic polyps, FasL expression was restricted to the luminal surface of the crypts, where Fas-FasL coexpression was coincident with a high frequency of TUNEL positive epithelial cells. All adenomas (n = 38) had an altered distribution of positive FasL staining; FasL expression was found in most cells (> 70% of neoplastic cells). Expression of Fas was also detected throughout the adenomas, but coexpression of FasL and Fas was not associated with TUNEL positivity in most cells.
conclusionsFasL upregulation occurs early in the adenoma-carcinoma sequence of colon carcinogenesis, and is evident at the level of mild dysplasia. The lack of pronounced apoptosis in areas of adenomas coexpressing Fas and FasL suggests that colonocytes acquire resistance to Fas mediated apoptosis early in the transformation process.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.